NewAmsterdam Pharma N.V. (NAMS) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
UroGen Pharma (URGN) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, gaining 113.4% versus a loss of 35.3%. Over five years, URGN leads with a +117.3% price change compared with +117.2% for NAMS. NewAmsterdam Pharma N.V. is the larger company by market cap ($2.52 billion vs $1.80 billion), about 1.4 times the size, while UroGen Pharma is growing revenue faster (+21.4% vs -50.6%).
UroGen Pharma converts more of its revenue into profit, with a net margin of -139.8% versus -905.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NAMS | URGN |
|---|---|---|
| Share price | $21.58 | $36.83 |
| Market cap | $2.52B | $1.80B |
| 1-day change | +1.48% | -0.41% |
| YTD return | -39.40% | +57.90% |
| 1-year return | -35.30% | +113.39% |
| 5-year return | +117.16% | +117.27% |
| Forward P/E | — | 13.18 |
| EPS (TTM) | $-2.16 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $22.50M | $109.79M |
| Revenue growth (YoY) | -50.61% | +21.45% |
| Net income (latest FY) | $-203.82M | $-153.49M |
| Gross margin | — | 88.66% |
| Operating margin | -1002.90% | -113.73% |
| Net margin | -905.74% | -139.81% |
| 52-week high | $42.21 | $50.81 |
| 52-week low | $20.91 | $15.86 |
| Distance from 52-week high | -48.88% | -27.51% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +130.13% | +62.91% |
| Average volume | 1.36M | 849.01K |
| Shares outstanding | 116.90M | 48.88M |
| Employees | 100 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed NAMS by 148.7 percentage points over the past year.
- UroGen Pharma is more profitable, keeping -139.8 cents of every revenue dollar as net income versus -905.7 cents for NewAmsterdam Pharma N.V..
- UroGen Pharma grew revenue faster in its latest fiscal year (+21.45% vs -50.61%).
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
NAMS vs URGN FAQ
Which is bigger, NewAmsterdam Pharma N.V. or UroGen Pharma?
NewAmsterdam Pharma N.V. (NAMS) is larger, with a market capitalization of $2.52B compared with $1.80B for UroGen Pharma (URGN).
Which stock has performed better over the past year, NAMS or URGN?
URGN returned +113.39% over the past 12 months, compared with -35.30% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are NewAmsterdam Pharma N.V. and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.